Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

@article{Eerenberg2011ReversalOR,
  title={Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects},
  author={E. Eerenberg and P. Kamphuisen and M. Sijpkens and J. Meijers and H. Buller and M. Levi},
  journal={Circulation},
  year={2011},
  volume={124},
  pages={1573–1579}
}
  • E. Eerenberg, P. Kamphuisen, +3 authors M. Levi
  • Published 2011
  • Medicine
  • Circulation
  • Background— Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC… CONTINUE READING
    1,328 Citations
    Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    • 518
    • Highly Influenced
    • PDF
    Reversal of novel oral anticoagulants in patients with major bleeding
    • 83
    • Highly Influenced
    Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
    • 201
    • PDF

    References

    SHOWING 1-10 OF 36 REFERENCES
    Oral rivaroxaban for symptomatic venous thromboembolism.
    • 1,981
    • PDF
    Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
    • 1,998
    • PDF